Skip to content

Advertisement

BMC Microbiology

  • Research article
  • Open Access

High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE−/− mice

BMC MicrobiologyBMC series – open, inclusive and trusted201616:264

https://doi.org/10.1186/s12866-016-0883-4

©  The Author(s). 2016

Received: 11 October 2015

Accepted: 29 October 2016

Published: 8 November 2016

Abstract

Background

Atherosclerosis appears to have multifactorial causes – microbial component like lipopolysaccharides (LPS) and other pathogen associated molecular patterns may be plausible factors. The gut microbiota is an ample source of such stimulants, and its dependent metabolites and altered gut metagenome has been an established link to atherosclerosis. In this exploratory pilot study, we aimed to elucidate whether microbial intervention with probiotics L. rhamnosus GG (LGG) or pharmaceuticals telmisartan (TLM) could improve atherosclerosis in a gut microbiota associated manner.

Methods

Atherosclerotic phenotype was established by 12 weeks feeding of high fat (HF) diet as opposed to normal chow diet (ND) in apolipoprotein E knockout (ApoE−/−) mice. LGG or TLM supplementation to HF diet was studied.

Results

Both LGG and TLM significantly reduced atherosclerotic plaque size and improved various biomarkers including endotoxin to different extents. Colonial microbiota analysis revealed that TLM restored HF diet induced increase in Firmicutes/Bacteroidetes ratio and decrease in alpha diversity; and led to a more distinct microbial clustering closer to ND in PCoA plot. Eubacteria, Anaeroplasma, Roseburia, Oscillospira and Dehalobacteria appeared to be protective against atherosclerosis and showed significant negative correlation with atherosclerotic plaque size and plasma adipocyte – fatty acid binding protein (A-FABP) and cholesterol.

Conclusion

LGG and TLM improved atherosclerosis with TLM having a more distinct alteration in the colonic gut microbiota. Altered bacteria genera and reduced alpha diversity had significant correlations to atherosclerotic plaque size, plasma A-FABP and cholesterol. Future studies on such bacterial functional influence in lipid metabolism will be warranted.

Keywords

AtherosclerosisProbioticsLGGTelmisartanGut microbitoa

Background

Atherosclerosis is the major cause of myocardial infarction and stroke, which accounts to the leading cause of death worldwide [1, 2]. Atherosclerosis is a chronic inflammatory disease of the arteries – inflammation is present and mediated by different chemokines/cytokines at all stages – from leukocytes recruitment by adhesion molecules in plaque formation to collagen cap digestions by metalloproteinases (MMPs) that contributes to the plaque instability.

Recently, there is more evidence that associates the gut microbiota to atherosclerosis. Endotoxin has become a popular candidate as the initiator of obesity and insulin resistance [3], not only can gut microbiota modulate endotoxemia [4], endotoxemia can also be resulted from a weakened gut barrier where endotoxin (LPS) and other bacterial products can easily leak into the circulation and trigger inflammatory response. Gastrointestinal (GI) track has been suggested to be the major site for pathogen associated molecular patterns (PAMPs) absorption and translocation [5]. Toll like receptors (TLRs) compose a family of recognition receptors for PAMPs, playing important roles in eliciting innate and adaptive immune responses [6]. TLR2, TLR4 and TLR5 can recognize and be activated by bacterial components found in the gut microbiota – peptidoglycan, LPS, and flagella respectively [7]. Inflammatory responses are augmented upon the activation of TLRs by NFκB and transcriptional activation of genes that encode pro-inflammatory cytokines and chemokines. With obesity and insulin resistance being major risk factors for atherosclerosis and cardiovascular diseases [8], it is not surprising to find endotoxin capable in accelerating and acts as a potent mediator for atherosclerosis [9–11]. Furthermore, presence and correlations of bacterial DNA in the atherosclerotic plaque to their abundance found in the GI tract had provided further support to potential causative links of the gut microbiota to atherosclerosis [12]. Investigations on modulating the gut microbiota in an attempt to reduce cardiovascular risks had increased significantly in the last decade – from realizing the potential of probiotics in improving lipid profile [13–16] and atherosclerotic plaque size [17, 18], and to finding the gut metagenome having a different functional capacity in symptomatic atherosclerotic patients [19], to recently identifying the gut microbiota dependent metabolites that significantly increase cardiovascular risks [20], have all contributed in assuring the metabolic role of gut microbes in atherosclerosis.

In this pilot study, we aimed to investigate whether probiotics and pharmaceutical interventions could improve atherosclerosis in a gut microbiota associated manner in a well-established atherosclerotic animal model, ApoE−/− mice [21–23]. L. rhamnosus GG (LGG), one of the best clinically-documented probiotic strains [24], was first isolated more than 20 years ago by Goldin and Gorbach from a faecal sample from a healthy adult and showed to have high resistance against gastric acid and high persistence capacity in the human GI tract [25]. As it has proven benefits in various diseases including diarrhea [26, 27], colitis [28] and atopic disease [29, 30]; and its high adaptability in the GI tract, LGG is often regarded as a model probiotic strain [31]. To better compare the capability and the extent to how LGG may improve atherosclerosis, a positive control was introduced by the pharmaceutical intervention of telmisartan (TLM). TLM is a dual angiotensin II receptor blocker and partial perixosome proliferator-activated receptor Ɣ (PPARƔ) agonist. Clinically, TLM is used to treat hypertension, including patients with atherosclerosis [32], and can improve endothelial [33] and cardiovascular [34] functions. In vivo, it was proven to relieve atherosclerosis in the ApoE−/− mice [35–37], and had recently been documented to reduce colonic inflammation in rats with inflammatory bowel disease [38]. We examined the effects of LGG and TLM supplementation in HF diet in terms of several atherosclerosis parameters and colonic gut microbiota, and identified some potentially important gut microbes in the pathogenesis of atherosclerosis.

Methods

Animals

Six-weeks-old female ApoE−/− mice were fed ad libitum on a normal chow diet for 1 week before being continued at normal chow diet (ND) (D10001, Research Diet) or powdered 21gm% high fat diet (D12079B, Research Diet) without (HF) or with Lactobacillus rhamnosus GG (LGG) (ATCC 53103) (Vailo) (HF + LGG) or telmisartan (TLM) (Micardis®, Boehringer Ingelheim GmbH) at 5 mg/kg/day (HF + TLM) for 12 weeks. Ingredients of the ND and HF diets can be found in Tables 1 and 2. For this pilot study, the number of mice used in ND, HF, HF + LGG and HF + TLM groups were 5, 4, 3 and 5 respectively. The dose of LGG at 1×108 CFU/day was converted from the recommended human dose using the Body Surface Area normalization method [39]. Lyophilized LGG powder was mixed in the HF diet; TLM was mixed into the drinking water – oral gavage was avoided to prevent stress induced immunomodulation. Fecal recovery of LGG has been tested to be at approximately 1×106CFU/g by fecal dilution and plating on LB plates (data not shown). Food and water consumption was monitored twice a week to adjust LGG or TLM dosages. All animals were kept in the Animal Laboratory of the Department of Surgery at 23–24 °C and relative humidity at 60–70 % on 12/12 h day/night cycle. All study protocols were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) of the University of Hong Kong and the Department of Health of the HKSAR Government.
Table 1

Protein, carbohydrate and fat content of ND and HF diet used in this pilot study

 

ND

HF

 

gm %

kcal %

gm %

kcal %

Protein

20.3

20.8

20

17

Carbohydrates

66

67.7

50

43

Fat

5

11.5

21

41

Total

 

100

 

100

kcal/gm

3.9

 

4.7

 
Table 2

Ingredients of ND and HF diet used in this pilot study

 

ND

HF

Ingredient

gm

kcal

gm

kcal

Caesin 30 Mesh

200

800

0

0

Caesin, 80 Mesh

0

0

195

780

DL-Methionine

3

12

3

12

Corn starch

150

600

50

200

Maltodextrin 10

0

0

100

400

Sucrose

500

2000

341

1364

Cellulose, BW200

50

0

50

0

Milk fat, anhydrous

0

0

200

1800

Corn oil

50

450

10

90

Mineral Mix S10001

35

0

35

0

Calcium carbonate

0

0

4

0

Vitamin Mix V10001

10

40

10

40

Choline Bitartrate

2

0

2

0

Cholesterol, USP

0

0

1.5

0

Ethoxyquin

0

0

0.04

0

Total

1000

3902

1001.54

4686

Quantification of plasma biomarkers

Mice were fasted overnight before sacrifice. Blood was collected in tubes coated with EDTA followed by centrifugation at 5,000 rpm for 10 min. Plasma was collected, aliquoted and stored at −80 °C until use. The plasma concentration of the following biomarkers were quantified using Milliplex™ MAP kits and Luminex 200 Analyzer (Merck Millipore) following the manufacturer’s protocol: ghrelin with Milliplex®MAP Mouse Gut hormone Panel; sE-selectin, MMP-9, sICAM-1 and sVCAM-1 with Milliplex®MAP Mouse Cardiovascular Disease Panel I kit; IL-33 with Milliplex®MAP Mouse Cytokine/Chemokine Panel III Immunoassay respectively; with data acquisition and basic data analysis using xPONENT 3.1 and advanced data analysis using Milliplex Analyst 3.5. Plasma A-FABP and cholesterol was quantified using Mouse Adipocyte FABP ELISA Kit (BioVendor Research and Diagnostic Products Brno) and Cholesterol Assay Kit (Cayman Chemical Company) respectively following manufacturer’s protocol. Plasma endotoxin was quantified with Lonza Limulus amebocyte lysate (LAL) QCL-1000 (Lonza) following manufacturer’s protocol with heat inactivation at 75 °C for 10 min and addition of β-glucan blocker (Lonza) (1:1) to inhibit false positive readings generated by contamination from β-1,3-glucans.

Assessment of atherosclerotic plaque size

Aortic sinus

Hearts were harvested, fixed in 4 % PFA overnight, embedded in Tissue-Tek® OCT compound (Sakura Finetek) and stored at −20 °C before cryosectioned serially at 10 μm intervals from the aortic sinus and mounted on slides (Superfrost plus). Oil Red O Solution was freshly prepared as previously described [40] and used within 2 h of preparation. Slides were stained with Leica ST5020 Multistainer (Leica Microsystems Inc) for better consistency. Briefly, slides were immersed in tap water for 2 min, 60 % isopropanol for 30s, Oil Red O Solution for 18 min, 60 % isopropanol for 30s, tap water for 2 min, hematoxylin for 2 min, tap water for 3 min, 2 % acetic acid for 3 s, tap water for 20 s, Bluing solution for 1 min and tap water for 1 min before air drying. Images for viewed and captured with Nikon 80i Microscope and lesion quantified using SPOT™ Software 4.7.

Aortic tree

Fat tissue and adventitious blood vessels were removed from the inferior vena cava carefully with micro-scissors and micro-dissection forceps under dissecting microscope. The inferior vena cava was harvested and stored in PBS at 4 °C until use. Sudan IV solution was prepared by preparing 0.5 % Sudan IV in 35 % ethanol and 50 % acetone followed by filtration. The artery was placed flat on a Petri dish, first rinsed with 70 % ethanol, stained with Sudan IV solution for 5 min and de-stained in 80 % ethanol for 6 min before being viewed under a Zoom Stereo Microscope (Olympus SZX7®) and images captured with an Olympus DP71 Microscope Digital Camera. Areas stained red were considered atherosclerotic lesions and were quantified using Image J software.

Colonial gut microbiota evaluation

DNA was extracted from colon using QIAamp® DNA Stool Mini Kit (Qiagen) followed by amplification of the V4-6 region of the 16S rRNA gene at position 563 to 1064 with a product size of 573 bp with Expand High FidelityPLUS PCR System (Roche). Each 25 μl of PCR mixture contained: 1× Expand High FidelityPLUS Reaction Buffer with 1.5 mM MgCl2; 200 μM PCR Grade Nucleotide Mix; 0.4 μM of the forward and reverse primers, 1.25U of Expand HiFiPLUS Enzyme Blend and 5–500 ng of template genomic DNA isolated from the mouse colon. The PCR protocol involved denaturation at 95 °C for 2 min; 35 cycles of denaturation at 95 °C for 20 s, annealing temperature at 53 °C for 30 s and extension at 72 °C for 40 s; and a final extension at 72 °C for 10 min. Target PCR products were verified on 1 % agarose gel with TAE buffer. A band of 573 bp was gel-purified with QIAquick® Gel Extraction Kit (Qiagen) and the final concentration of the amplicon was quantified using Quant-iT™PicoGreen® dsDNA assay (Invitrogen). Library preparation, emPCR amplification and picotitre plate pyrosequencing using titanium chemistry was carried out in accordance with Roche/454 Life Sciences protocols on the 454 GS Junior (454 Life Sciences-a Roche Company). A total of 397,743 sequence reads were generated, with an average of 23,397 reads per sample. All sequence reads derived from the 454 GS Junior pyrosequencer were analyzed using Quantitative Insights Into Microbial Ecology (QIIME) [41]. Prior to sequence analysis, all raw reads were denoised to reduce sequencing errors and avoid artificial inflation of OTU diversity and processed for quality trimming. Quality trimming parameters included removal of forward and reverse primer sequences, retaining a minimum sequence length of 150 bp; maximum sequence length of 573 bp; minimum quality score of 25 in a 50 bp sliding window. Quality trimmed reads were demultiplexed based on pre-designed barcodes followed by determination of operational taxonomic units (OTUs) by clustering sequences with a similarity threshold of 97 % using uclust. Representative sequences were picked and aligned using MUSCLE (Multiple Sequence by Log-Expectation) against the Greengenes Core Set data followed by taxonomy assignment to each sequence using the Blast algorithm after screening and eliminating chimeric reads. Subsequent analysis included relative and absolute abundance of bacteria, alpha and beta diversity and principal coordinates (PCoA) plots based on unweighted UniFrac using inherent scripts within the QIIME package. All 454 sequence data associated with this study has been deposited in the NCBI SRA repository under the study accession no. SRP026050.

Statistical analysis

Data are expressed as mean ± SEM. Data normality was analyzed using Shapiro-Wilk test [42]. Kruskal-Wallis Test with Dunns post hoc tests were used to analyze nonparametric data; One Way ANOVA with Bonferroni post hoc tests were used to analyze parametric data. Statistical tests were done using GraphPad Prism 5. Correlation studies were done using R [43]. P < 0.05 was considered statistically significant.

Results

LGG and TLM significantly reduced high fat diet induced atherosclerosis plaque size at aortic sinus and aortic tree

The lesion at the aortic root (Fig. 1a LHS) and aortic tree (Fig. 1b and magnified at Fig. 1a RHS) was stained red with Oil Red O and Sudan IV respectively. 12 weeks of HF diet significantly increased lesion area in ApoE−/− mice at the aortic sinus by 8 fold, from a mean for ND at 0.06 mm2 to HF at 0.59 mm2. LGG and TLM supplementation reduced the lesion size by 37 % (0.37 mm2) and 80 % (0.12 mm2) respectively (Fig. 1c). Comparable results were seen at the aortic tree – the lesion area in HF was 2.21 fold higher than ND (0.12 cm2 vs 0.04 cm2, respectively), while LGG and TLM supplementation led to a 33 % (0.08 cm2) and 58 % (0.05 cm2) reduction respectively (Fig. 1d). TLM was effective in restricting the HF diet induced atherosclerotic plaques at the aortic sinus and the aortic tree to a level close to that is seen in the ND group.
Figure 1
Fig. 1

Atherosclerotic plaque characterization. Lipid was stained red with Oil Red O at the aortic sinus (a, LHS), and Sudan IV in the aortic tree (b) (Ascending aorta, arch of aorta, part of the descending aorta, brachiocephalic artery, left common carotid artery and left subclavian artery was magnified at the RHS of a); the size of the lesion area at the aortic sinus (c) and the entire aortic tree (d) was quantified using ImageJ. Significant difference of ND from the HF group was denoted by ### P < 0.001; significant difference of the treatment groups from HF group was donated by ***P < 0.001. ApoE−/− mice were fed on either normal chow diet (ND) or high fat (HF) diet with or without LGG (1×108CFU/day) or TLM (5 mg/kg/day)

HF diet led to cholesterol crystals formation in plaque and worsened various atherosclerosis related biomarker levels which were improved by LGG and TLM to different extents

Atherosclerosis is associated with worsened lipid and adipokine profile, as well as various inflammation related biomarkers. HF diet led to formation of cholesterol crystals in the atherosclerotic plaque that were not observed in the other groups (Fig. 2a). HF diet significantly elevated plasma levels of A-FABP, cholesterol, MMP-9, sE-selectin, sICAM-1, sVCAM-1 and endotoxin. Supplementing LGG in HF diet significantly decreased such elevation except MMP-9; while TLM reduced the plasma levels of A-FABP, MMP-9, sE-selectin, sVCAM-1 and endotoxin (Fig. 2, b, c, d, e, f, g & h). On the other hand, while HF diet did not induce any significant change in plasma level of ghrelin nor IL-33, they were significantly increased by TLM supplementation (Fig. 3h, i).
Figure 2
Fig. 2

Cholesterol crystals in atherosclerotic plaque and plasma concentrations of atherosclerosis related biomarkers. Atherosclerotic plaque stained with Oil Red O at the aortic sinus, with blue arrows indicating the cholesterol crystals (a). Plasma concentration of A-FABP (b); cholesterol (c); MMP-9 (d); sE-selectin (e); sVCAM-1 (f); sICAM-1 (g); endotoxin (h); ghrelin (i) and IL-33 (j). Significant difference of ND from the HF group was denoted by # PP < 0.05, ## P < 0.01, ### P < 0.001; significant difference of the treatment groups from HF group was donated by *P < 0.05, **P < 0.01, ***P < 0.001. ApoE−/− mice were fed on either normal chow diet (ND) or high fat (HF) diet with or without LGG (1×108CFU/day) or TLM (5 mg/kg/day)

Figure 3
Fig. 3

Colonic gut microbiota alterations. Absolute abundances of (a) Firmicutes, (b) Bacteroidetes and the ratio of Firmicutes over Bacteroidetes (c); relative abundances of 18 bacteria at genus level with raw counts of at least 100 (d); Venn diagram summarizing number of OTUs shared between different groups (e); alpha diversity indexes including number of observed species (f) and Chao1 index (g); beta diversity indicated by PCoA plot of unweighted UniFrac distance showing sample clustering by treatment groups (h). Significant difference of ND from the HF group was denoted by # P < 0.05, ## P < 0.01; significant difference of the treatment groups from HF group was donated by *P < 0.05. ApoE−/− mice were fed on either normal chow diet (ND) or high fat (HF) diet with or without LGG (1x108CFU/day) or TLM (5 mg/kg/day)

HF diet distorted colonial microbial profile and reduced bacterial diversity, which were counteracted by TLM but not LGG

In assessing statistically significant alterations in the bacterial community, only those taxa for which raw counts reached at least 100 were considered. At the phylum level, while no treatment group led to significant change in the abundance of Firmicutes (Fig. 3a), HF diet in general had led to significant decrease in Bacteroidetes (Fig. 3b). The ratio Firmicutes/Bacteroidetes (F/B), which usually increases during obese states and dysbiosis [44, 45], was markedly elevated by HF diet. Supplementing LGG and TLM in HF diet trended and significantly lowered F/B respectively (Fig. 3c). At the genera level, HF diet had led to significantly lower colonial abundances of Eubacterium, Anaeroplasma, Oscillospira, Roseburia and Dehalobacterium and higher abundances of Allobaculum, Clostridum, Lactobacillus and Bifidobacteria when compared to ND. The HF + LGG group had significantly higher Lactobacillus and Clostridum abundances compared to the ND and HF + TLM group; whereas the HF + TLM group had significantly higher Helicobacter abundance than HF alone (Fig. 3d).

The degree of OTUs shared between individual mice and the four groups was summarized in the Venn diagram (Fig. 3e). Greatest numbers of OTUs were shared between mice in the same group. With respect to the ND-HF comparison, 125 OTUs were common to both groups while a large number of OTUs were still unique to each group (370 for ND; 76 for HF). The HF + TLM group (174) had a greater overlap with the ND group OTUs compared to the HF + LGG group (117), revealing a more potent effect in maintaining normal bacterial composition in the colon. The core microbiome comprised 79 OTUs that were present regardless of manipulations to the diet.

Overall bacterial species diversity within the four groups was examined using alpha diversity indexes including observed number of species (Fig. 3f) and the chao1 index (Fig. 3g). The HF diet significantly reduced the number of observed species (221 ± 27) compared to the ND (381 ± 11). While the LGG supplementation did not change the number of observed species (179 ± 4) compared to HF diet alone, significant increase was seen with TLM supplementation (265 ± 31). The number of observed species in both the HF + LGG and HF + TLM groups remained significantly lower than the ND group (Fig. 3f). The impact of the HF diet was similarly indicated (reduction in diversity) through the Chao1 index (Fig. 3g). The significant higher number of observed species and Chao1 index suggests that species richness in the ND group was populated by the presence of many more rare species. The unweighted UniFrac PCoA plot revealed clear microbial diversity demarcation resulting from a HF diet compared to the ND group. Mice of HF + LGG or HF + TLM groups aggregated into distinct clusters as well based on their bacterial communities (Fig. 3h).

Lowered bacterial diversity and alterations in several colonic bacterial genera highly associated with changes in several atherosclerosis parameters

As ND and HF had the most drastic differences detected in atherosclerosis lesion size (Fig. 1), related biomarkers (Fig. 2) and gut microbial abundances (Fig. 3), correlations between the atherosclerotic parameters and bacterial taxa were investigated between the groups (Fig. 4). Only bacterial genera with an accumulative count of at least 100 across all samples were studied. Of these, genera that showed statistically significant abundance difference between ND and HF group were selected for the correlation analysis. The HF diet induced significantly lowered number of observed species and chao1 index; as well as the colonic abundances of Eubacterium, Anaeroplasma, Oscillospira, Dehalobacterium and Roseburia (p < 0.05) showed significant negative correlations to the increase in lesion size at the aortic sinus (p < 0.05). Moreover, the reduction of the number of observed species, chao1 index and abundances of Eubacterium, Anaeroplasma and Oscillospira showed significant negative correlations with lesion area of the entire aortic tree, plasma A-FABP and cholesterol. Reduction in Eubacterium also showed significant negative correlation with increase in MMP-9 and sE-selectin; similar observations were also seen between Dehaobacterium with A-FABP and Roseburia with MMP-9. Notably decrease in Roseburia showed positive correlations to the decrease in plasma IL-33. (Fig. 4). In contrast, HF diet induced significant increase in abundances of Lactobacillus, Allobaculum, Clostridium and Bifidobacterium (p < 0.05), of which Clostridium and Bifidobacterium showed significant positive correlations with atherosclerotic lesion size at the sinus, aortic tree, plasma A-FABP, cholesterol, MMP-9 or sE-selectin (Fig. 4).
Figure 4
Fig. 4

Heat map describing the correlation of the alpha diversity and abundances of different colonic bacterial genera and atherosclerosis parameters. Bacteria genera shown were significantly altered (P < 0.05) by HF diet feeding in ApoE−/− mice. The colors range from blue (negative correlation; −1) to red (positive correlation; +1). Significant correlations were noted by *P < 0.05, **P < 0.01 and ***P < 0.001; strong tendency of correlation was noted by ^P < 0.10

Likewise, when correlations were analyzed between HF & HF + LGG groups or HF & HF + TLM groups, significant or strong tendency of similar correlations as noted between ND & HF groups were observed, especially between Eubacterium, Dehalobacterium, Roseburia and Clostridium and lesion size, A-FABP and cholesterol (Data not shown). Such correlations were not as strong probably due to as compared to HF & ND, supplementing LGG or TLM to HF induced a relatively smaller changes in atherosclerotic parameters and changes in bacterial genera abundances.

Discussion

From the earlier studies that showed bacterial abundances in atherosclerotic plaques correlating with those in the gastrointestinal tract [12]; patients with symptomatic atherosclerosis having an altered gut microbial abundances and metagenome that was enriched in genes encoding peptidoglycan synthesis but depleted in those for phytoene dehydrogenase [19]; to recently identifying gut microbiota dependent metabolites including trimethylamine-N-oxide (TMAO) and Ɣbutyrovbetaine (ƔBB) from dietary phosphatidylcholine and L-carnitine, that serve as strong predictors of coronary artery disease [20, 46], have all suggested the gut microbiota as a very potential therapeutic target for reducing atherosclerosis associated cardiovascular disease risks.

In this pilot study, we have first induced a strong atherosclerotic phenotype with HF diet in ApoE−/− mice – including significantly increase in atherosclerotic plaque size and undesirable levels of atherogenic biomarkers; then we compared the effects induced by microbial (LGG) and pharmaceutical (TLM) intervention in terms of gut microbial changes and different atherosclerosis associated parameters. One limitation of the current study is the relatively small sample size. As a pilot study, a smaller animal numbers is typically used to generate data as the foundation for future experiments. For example, exciting insights have been generated from some pilot studies with limited number of animals for further studies [47, 48]. With our previous experience in the lesion size expected in normal chow or high fat diet in the ApoE−/− mice, the current number of mice used were justified in generating meaningful statics [49]. In essence, we have found the following from the pharmaceutical or probiotic intervention of gut microbiota in relevance to the development of atherosclerosis:

Firstly, we found that both LGG and TLM could significantly reduce HF diet induced atherosclerotic plaque size, where TLM had a stronger plaque reducing power (Fig. 1). While TLM is used as a control to reduce atherosclerotic plaque size in ApoE−/− mice [35–37], certain probiotics including L. acidophilus ATCC 4358 [18] and Enterococcus faecium CRL183 & L. helveticus 416 [17] had been previously shown to reduce atherosclerotic plaque size in ApoE−/− mice and rabbits on hypercholesterolemic diet respectively. Such reduction might be modulated through lowering oxidative stress and inflammation [18].

Secondly, we showed that atherosclerotic improvement led by LGG and TLM were indicative by several associated biomarkers. LGG could reduce the HF diet induced lipid related parameters including cholesterol and A-FABP, an adipokine that is an important player in lipid metabolism and a pathophysiological mediator of atherosclerosis [50]. Cholesterol reduction has been implied for lesser cardiovascular events owing to the resultant anti-inflammatory effects, improved plaque stability and reduced risk of thrombotic complications [51]. While some probiotics had shown hypocholesterolemic effects clinically [52, 53], the effects are likely to be strain specific as others have failed to show the same effect [54, 55]. Supplementation of LGG or TLM to HF diet also resulted in reduction of cholesterol crystals in the atherosclerotic plaque. As cholesterol crystals have been suggested to be capable of physically perforating cell membranes and the plaque cap, subsequently triggering cell apoptosis and plaque rupture respectively [56, 57], LGG and TLM could have further conferred plaque stability. LGG also reduced soluble E-selectin, ICAM-1 and VCAM-1, contributing to a less atherogenic environment. Furthermore, LGG reduced endotoxemia, a promising candidate that initiates obesity and insulin resistance [3]. Indeed, probiotics had been suggested in quite a few studies to be beneficial to cardiovascular system by improving lipid profiles [13, 16, 58] and endotoxemia [58]. One potential mechanism to how LGG improved lipid profile was its ability to produce exopolysaccharides [59]. Exopolysaccharides can serve as a protective shield for LGG to fight against the host innate immunity [60] and at the same time modify the enteric gut microbiota and reduce liver and serum cholesterol and triglyceride concentrations [59]. Certain L. rhamnosus strains can also produce specific delipidating molecules, such as conjugated linoleic acid [61, 62] that interfere with host metabolism by modulating energy expenditure, fatty acid oxidation, lipolysis and lipogenesis [61]. While LGG induced a relatively less alteration in the gut microbial abundances in this study, it should be noted that the lipid modulating effects exerted by Lactobacillus can be independent to its intestinal colonization [63].

TLM resulted in similar significant or trended reduction in the tested plasma biomarkers, especially in MMP-9 and endotoxin. The inhibitory effects of TLM on A-FABP [64, 65] and monocytic cell adhesions [66] may have been mediated by PPARƔ activation; and on MMP-9 [67–72] by Elk-1 phosphorylation inhibition [67]. While TLM was previously shown to lower cholesterol [73, 74], possibly through inhibiting intestinal cholesterol absorption [74], such reduction was not seen in the current study. Interestingly, TLM was able to increase plasma ghrelin and IL-33 concentrations, suggesting TLM may contribute to an anti-atherogenic environment by mediating Th1 to Th2 responses [75, 76].

Thirdly, we demonstrated that HF diet induced atherosclerosis was associated with a much lower colonic microbial diversity. The reduced microbial diversity may be from the selected growth of bacteria that better utilized fatty acids as their energy source, leading to their dominances and out-competing the growth of others. Resistance to pathogenic bacteria colonization may be reduced resulting in worsened gut barrier functions. Although LGG did not increase gut microbial diversity and a less distinct clustering in the PCoA plot that was further away from ND in this study, L. plantarum had been shown to increase bacterial diversity in the colon in men with incipient atherosclerosis [77]. The restoration of bacterial diversity by TLM suggests that supplementing TLM was able to blunt the drop in the microbial assemblage, its potential ability to sustain a more diverse bacterial community despite the same HF content.

Furthermore, we have identified five bacteria genera that are most likely protective against atherosclerosis – Eubacerium, Anaeroplasma, Oscillospira, Roseburia and Dehalobacterium. These microbes correlated strongly with atherosclerotic lesion area at the aortic sinus and aortic tree, plasma cholesterol, A-FABP and MMP-9. Recently, Eubacterium and Roseburia were found to be enriched in the gut microbiota in healthy controls against those with symptomatic atherosclerosis [19]. Eubacteria and Roseburia, in our pilot study, were at much higher abundance in the ND and HF + LGG groups compared to the HF group. As Eubacteria and Roseburia are butyrate producing bacteria [78, 79], they may inhibit proliferation of vascular smooth muscle cells [80] conferring athero-protective effects. Oscillospira is often found strongly increased in hosts fed on fresh green fields [81], and Anaeroplasma is correlated with better crude fiber digestibility [82]. Higher abundances of Oscillospira and Anaeroplasma may have conferred protective effects based on their capacity on fiber metabolism. For example, O. guillermondii, together with a more abundant network of primary fiber degraders were found associated with lower BMI [83].

On the other hand, HF diet had significantly enhanced the colonic population of Lactobacillus, Allobaculum, Bifidobacterium and Clostridium, among which the increase in Bifidobacterium and Clostridium were positively correlated to atherosclerotic plaque size, A-FABP and cholesterol. The main elevated Bifidobacteria species in the HF group was B. pseudologum, which is the most predominant Bifidobacterium species in the infant gut [84] but insufficiently understood. Interestingly, Bifidobacterium were also found to have a significant positive correlation with TMAO, the gut microbiota dependent metabolite that predicts CVD risks [85]. With the complete genome of B. pseudologum completed [86], the functional capacity of the Bifidobacterium genera should be further explored for its relationship with atherosclerosis. Clostridium cocleatum, which was significantly elevated in the HF group, can degrade mucin [87] thus could impair the gut barrier and thereby augment systemic inflammation. As for Allobaculum, which correlated positively with atherosclerotic plaque size and MMP-9 in our pilot study, and TMAO in others [85], was also associated with low fat [88] and prebiotics [89] feeding. Lactobacillus, while being elevated in the HF diet, did not have any significant correlation with the atherogenic parameters tested in this study. So far, certain Lactobacillus species had been associated with obesity and weight gains while others with weight loss, for example, L. reuteri enrichment and L. casei/paracasei and L. plantanum depletion in an obese gut metagenome [90]. The complete genomes of seven different weight gain or weight protection associated Lactobacillus were recently sequenced and genes involved in carbohydrates and lipid metabolism and bacteriocin were identified to have a prominent role in nutrients harvesting and defense against oxidative stress [91], thus contributing to their associations to pro/anti-obesity.

Conclusion

In this pilot study, we showed that microbial intervention with LGG or pharmaceutical intervention with Telmisartan were effective in reducing atherosclerotic plaque size and improveing plasma levels of various atherosclerosis associated biomarkers to different extents. TLM was more effective than LGG in altering the gut microbiota – in terms of colonic bacterial diversity and abundances closer to that observed when fed a ND diet. A lowered colonic bacterial diversity, abundances of Eubacterium, Anaeroplasma, Roseburia, Oscillospira, Dehalobacterium and increased Clostridium and Bifidobacteria was associated with an adverse atherogenic profile, especially atherosclerotic plaque size, plasma levels of A-FABP and cholesterol. As A-FABP, a suggested nexus where nutritional and inflammatory pathways meet [92], and cholesterol are crucial players in lipid metabolism, future studies focusing on the functional capacities in lipid metabolism of the above-mentioned bacteria will be valuable in understanding their impact on atherogenic development and to understand whether they are an active conspirator to pathology or a silent reflection of disease progression/outcome.

Abbreviations

A-FABP: 

Adipocyte fatty acid binding protein

ApoE−/−: 

Apolipoprotein E knockout

ƔBB: 

Ɣ-butyrobetaine

GI: 

Gastrointestinal

HF: 

High fat

LGG: 

Lactobacillus rhamnosus GG

LPS: 

Lipopolysaccharides

MMPs: 

Metalloproteinases

ND: 

Normal diet

OTU: 

Operational taxonomic units

PAMPs: 

Pathogen associated molecular patterns

PCoA: 

Principal coordinates

PPARƔ: 

Perixosome proliferator-activated receptor Ɣ

QIIME: 

Quantitative insights into microbial ecology

sE-selectin: 

Soluble E-selectin

sICAM-1: 

Soluble intercellular adhesion molecule – 1

sVCAM-1: 

Soluble vascular cell adhesion molecule – 1

TLM: 

Telmisartan

TMAO: 

Trimethylamine-N-oxide

Declarations

Acknowledgments

We would like to thank Dr. Aimin Xu from the Department of Medicine, University of Hong Kong for kindly providing the ApoE−/− mouse model and Prof. Seppo Salminen from Functional Food Forum, University of Turku for his comments on the manuscript.

Funding

The work was supported by Small Grant Fund, The University of Hong Kong. PV.K. was funded by the Academy of Finland and the Finnish Funding Agency for Technology and Innovation.

Availability of data and materials

All 454 sequence data associated with this study has been deposited in the NCBI SRA repository under the study accession no. SRP026050.

Authors’ contributions

YKC performed and analyzed all experiments and drafted the first manuscript. MSB led bioinformatics analysis and revised manuscript. JP and DL helped data acquisition. PVK, YC, HE and FCCL contributed to experimental concept and design. HE, YC and PVK revised the manuscript for important intellectual content. HE gave final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests

All authors declare no conflict of interests.

Consent for publication

Not applicable.

Ethics approval

All study protocols were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) of the University of Hong Kong and the Department of Health of the HKSAR Government.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
5S12, Kadoorie Biological Sciences Building, School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong
(2)
5N01, Kadoorie Biological Sciences Building, School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong
(3)
Food and Research Health Centre, University of Eastern Finland, Joensuu, Finland
(4)
L943, Laboratory Block, Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
(5)
Bioinformatics Center, Nanjing Agricultural University, Nanjing, China
(6)
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
(7)
5S13, Kadoorie Biological Sciences Building, The University of Hong Kong, Pokfulam, Hong Kong

References

  1. Loscalzo J, editor. Molecular mechanisms of atherosclerosis. Haddington: Taylor & Francis; 2005.Google Scholar
  2. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297–329. doi:10.1146/annurev.pathol.1.110304.100100.View ArticlePubMedGoogle Scholar
  3. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72. doi:10.2337/db06-1491.View ArticlePubMedGoogle Scholar
  4. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathologie-biologie. 2008;56(5):305–9. doi:10.1016/j.patbio.2007.09.008.View ArticlePubMedGoogle Scholar
  5. Erridge C. Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis. 2011;216(1):1–6. doi:10.1016/j.atherosclerosis.2011.02.043.View ArticlePubMedGoogle Scholar
  6. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430(6996):257–63. doi:10.1038/nature02761.View ArticlePubMedGoogle Scholar
  7. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131–44. doi:10.1038/nri2707.View ArticlePubMedGoogle Scholar
  8. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106(4):453–8. doi:10.1172/JCI10762.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999;34(7):1975–81.View ArticlePubMedGoogle Scholar
  10. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(12):2227–36. doi:10.1161/01.ATV.0000147534.69062.dc.View ArticlePubMedGoogle Scholar
  11. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich M, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation. 2001;104(8):914–20.View ArticlePubMedGoogle Scholar
  12. Koren O, Spor A, Felin J, Fak F, Stombaugh J, Tremaroli V, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4592–8. doi:10.1073/pnas.1011383107.View ArticlePubMedGoogle Scholar
  13. Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, Yang JS, et al. Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28. Benefic Microbes. 2012;3(1):13–22. doi:10.3920/BM2011.0046.View ArticleGoogle Scholar
  14. Stancu CS, Sanda GM, Deleanu M, Sima AV. Probiotics determine hypolipidemic and antioxidant effects in hyperlipidemic hamsters. Mol Nutr Food Res. 2014;58(3):559–68. doi:10.1002/mnfr.201300224.View ArticlePubMedGoogle Scholar
  15. Tomaro-Duchesneau C, Saha S, Malhotra M, Jones ML, Labbe A, Rodes L, et al. Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Appl Microbiol Biotechnol. 2014;98(1):115–26. doi:10.1007/s00253-013-5252-8.View ArticlePubMedGoogle Scholar
  16. Huang Y, Wang X, Wang J, Wu F, Sui Y, Yang L, et al. Lactobacillus plantarum strains as potential probiotic cultures with cholesterol-lowering activity. J Dairy Sci. 2013;96(5):2746–53. doi:10.3168/jds.2012-6123.View ArticlePubMedGoogle Scholar
  17. Cavallini DC, Suzuki JY, Abdalla DS, Vendramini RC, Pauly-Silveira ND, Roselino MN, et al. Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model. Lipids Health Dis. 2011;10:126. doi:10.1186/1476-511X-10-126.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Chen L, Liu W, Li Y, Luo S, Liu Q, Zhong Y, et al. Lactobacillus acidophilus ATCC 4356 attenuates the atherosclerotic progression through modulation of oxidative stress and inflammatory process. Int Immunopharmacol. 2013;17(1):108–15. doi:10.1016/j.intimp.2013.05.018.View ArticlePubMedGoogle Scholar
  19. Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. doi:10.1038/ncomms2266.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Troseid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277(6):717–26. doi:10.1111/joim.12328.View ArticlePubMedGoogle Scholar
  21. Jawien J. The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis. Curr Pharm Biotechnol. 2012;13(13):2435–9.View ArticlePubMedGoogle Scholar
  22. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm Des. 2008;14(4):338–51.View ArticlePubMedGoogle Scholar
  23. Daugherty A. Mouse models of atherosclerosis. Am J Med Sci. 2002;323(1):3–10.View ArticlePubMedGoogle Scholar
  24. Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol Clin N Am. 2005;34(3):483–98. doi:10.1016/j.gtc.2005.05.011. ix.View ArticleGoogle Scholar
  25. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol. 1999;65(1):351–4.PubMedPubMed CentralGoogle Scholar
  26. Vanderhoof JA, Whitney DB, Antonson DL, Hanner TL, Lupo JV, Young RJ. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr. 1999;135(5):564–8.View ArticlePubMedGoogle Scholar
  27. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54–60.View ArticlePubMedGoogle Scholar
  28. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet. 1987;2(8574):1519.View ArticlePubMedGoogle Scholar
  29. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357(9262):1076–9. doi:10.1016/S0140-6736(00)04259-8.View ArticlePubMedGoogle Scholar
  30. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003;361(9372):1869–71. doi:10.1016/S0140-6736(03)13490-3.View ArticlePubMedGoogle Scholar
  31. Lebeer S, Claes IJ, Verhoeven TL, Vanderleyden J, De Keersmaecker SC. Exopolysaccharides of Lactobacillus rhamnosus GG form a protective shield against innate immune factors in the intestine. Microb Biotechnol. 2011;4(3):368–74. doi:10.1111/j.1751-7915.2010.00199.x.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Welch H, Randall WA, Putnam LE, Hendricks FD. The effect of prolonged use of penicillin tooth powder on the penicillin resistance of oral microorganisms. Antibiot Chemother. 1952;2(5):249–54.Google Scholar
  33. Zankl AR, Ivandic B, Andrassy M, Volz HC, Krumsdorf U, Blessing E, et al. Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clin Res Cardiol. 2010;99(12):787–94. doi:10.1007/s00392-010-0184-0.View ArticlePubMedGoogle Scholar
  34. Mizuguchi Y, Oishi Y, Miyoshi H, Iuchi A, Nagase N, Oki T. Telmisartan improves morphologic and functional changes in both left ventricular myocardium and carotid arterial wall in patients with hypertension: assessment by tissue Doppler imaging and carotid ultrasonography. Echocardiography. 2010;27(7):864–72. doi:10.1111/j.1540-8175.2010.01163.x.View ArticlePubMedGoogle Scholar
  35. Blessing E, Preusch M, Kranzhofer R, Kinscherf R, Marx N, Rosenfeld ME, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199(2):295–303. doi:10.1016/j.atherosclerosis.2007.10.037.View ArticlePubMedGoogle Scholar
  36. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186(2):402–10. doi:10.1016/j.atherosclerosis.2005.08.009.View ArticlePubMedGoogle Scholar
  37. Zhao Y, Zhao S, Kuge Y, Strauss HW, Blankenberg FG, Tamaki N. Attenuation of apoptosis by telmisartan in atherosclerotic plaques of apolipoprotein E−/− mice: evaluation using technetium 99 m-annexin A5. Mol Imaging. 2013;12(5):300–9.PubMedGoogle Scholar
  38. Arab HH, Al-Shorbagy MY, Abdallah DM, Nassar NN. Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease. PloS one. 2014;9(5):e97193. doi:10.1371/journal.pone.0097193.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Reagan-Shaw S, Nihai M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659–61.View ArticlePubMedGoogle Scholar
  40. Baglione J, Smith JD. Quantitative assay for mouse atherosclerosis in the aortic root. Methods Mol Med. 2006;129:83–95. doi:10.1152/ajpendo.90617.2008.PubMedGoogle Scholar
  41. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335–6. doi:10.1038/nmeth.f.303.View ArticlePubMedPubMed CentralGoogle Scholar
  42. A A. Shapiro-Wilk Test Calculator SciStatCalc 2013. http://scistatcalc.blogspot.hk/2013/10/shapiro-wilk-test-calculator.html. Accessed 28 May 2016.
  43. Team RDC. R: A language and environment for statistical computing. R Function for Statistical Computing: Vienna, Austria; 2008.Google Scholar
  44. Chan YK, Estaki M, Gibson DL. Clinical consequences of diet-induced dysbiosis. Ann Nutr Metab. 2013;63 Suppl 2:28–40. doi:10.1159/000354902.View ArticlePubMedGoogle Scholar
  45. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005;102(31):11070–5. doi:10.1073/pnas.0504978102.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Koeth RA, Levison BS, Culley MK, Buffa JA, Wang Z, Gregory JC, et al. gamma-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799–812. doi:10.1016/j.cmet.2014.10.006.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Pfeifer CG, Kinsella SD, Milby AH, Fisher MB, Belkin NS, Mauck RL, et al. Development of a large animal model of osteochondritis dissecans of the knee: a pilot study. Orthop J Sports. 2015;3(2):2325967115570019. doi:10.1177/2325967115570019.Google Scholar
  48. Christofidou-Solomidou M, Pietrofesa R, Arguiri E, Mcalexander MA, Witwer KW. Dietary flaxseed modulates the miRNA profile in irradiated and non-irradiated murine lungs: a novel mechanism of tissue radioprotection by flaxseed. Cancer Biol Ther. 2014;15(7):930–7. doi:10.4161/cbt.28905.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Sample size/power calculations. Division of biomathematics/biostatistics, Department of Pediatrics, Columbia University Medical Centre. Available at: http://www.biomath.info/power/index.htm. Accessed 28 May 2016.
  50. von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012;32(9):2327–35. doi:10.1161/ATVBAHA.112.248609.View ArticleGoogle Scholar
  51. Libby P, Aikawa M, Schonbeck U. Cholesterol and atherosclerosis. Biochim Biophys Acta. 2000;1529(1–3):299–309.View ArticlePubMedGoogle Scholar
  52. Ramakrishnan U, Kuklina E, Stein AD. Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr. 2002;76(6):1256–60.PubMedGoogle Scholar
  53. Bertolami MC, Faludi AA, Batlouni M. Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. Eur J Clin Nutr. 1999;53(2):97–101.View ArticlePubMedGoogle Scholar
  54. Hatakka K, Mutanen M, Holma R, Saxelin M, Korpela R. Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr. 2008;27(4):441–7.View ArticlePubMedGoogle Scholar
  55. Simons LA, Amansec SG, Conway P. Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis. 2006;16(8):531–5. doi:10.1016/j.numecd.2005.10.009.View ArticlePubMedGoogle Scholar
  56. Abela GS. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J Clin Lipidol. 2010;4(3):156–64. doi:10.1016/j.jacl.2010.03.003.View ArticlePubMedGoogle Scholar
  57. Suhalim JL, Chung CY, Lilledahl MB, Lim RS, Levi M, Tromberg BJ, et al. Characterization of cholesterol crystals in atherosclerotic plaques using stimulated Raman scattering and second-harmonic generation microscopy. Biophys J. 2012;102(8):1988–95. doi:10.1016/j.bpj.2012.03.016.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Toral M, Gomez-Guzman M, Jimenez R, Romero M, Sanchez M, Utrilla MP, et al. The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clin Sci. 2014;127(1):33–45. doi:10.1042/CS20130339.View ArticlePubMedGoogle Scholar
  59. Enserink M. Profile: Helga Nowotny. Keeping Europe’s basic research agency on track. Science. 2011;331(6021):1134–5. doi:10.1126/science.331.6021.1134.View ArticlePubMedGoogle Scholar
  60. De Riggo J, Benco M, Kolarovszki B, Luptak J, Svihra J. Urinary incontinence in degenerative spinal disease. Acta Chir Orthop Traumatol Cechoslov. 2011;78(1):67–70.Google Scholar
  61. Lee K, Paek K, Lee HY, Park JH, Lee Y. Antiobesity effect of trans-10, cis-12-conjugated linoleic acid-producing Lactobacillus plantarum PL62 on diet-induced obese mice. J Appl Microbiol. 2007;103(4):1140–6. doi:10.1111/j.1365-2672.2007.03336.x.View ArticlePubMedGoogle Scholar
  62. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761(7):736–44. doi:10.1016/j.bbalip.2006.05.007.View ArticlePubMedGoogle Scholar
  63. Bjerg AT, Sorensen MB, Krych L, Hansen LH, Astrup A, Kristensen M, et al. The effect of Lactobacillus paracasei subsp. paracasei L. casei W8(R) on blood levels of triacylglycerol is independent of colonisation. Benefic Microbes. 2015;6(3):263–9. doi:10.3920/BM2014.0033.View ArticleGoogle Scholar
  64. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5):993–1002. doi:10.1161/01.HYP.0000123072.34629.57.View ArticlePubMedGoogle Scholar
  65. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109(17):2054–7. doi:10.1161/01.CIR.0000127955.36250.65.View ArticlePubMedGoogle Scholar
  66. Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 2011;3(6):631–8. doi:10.1159/000329115.View ArticlePubMedGoogle Scholar
  67. Zhang R, Jiang F, Chen CS, Wang T, Feng J, Tao T, et al. Serum Levels of IL-1 beta, IL-6, TGF- beta, and MMP-9 in patients undergoing carotid artery stenting and regulation of MMP-9 in a new in vitro model of THP-1 cells activated by stenting. Mediat Inflamm. 2015;2015:956082. doi:10.1155/2015/956082.Google Scholar
  68. Zhu C, Zhang X, Qiao H, Wang L, Zhang X, Xing Y, et al. The intrinsic PEDF is regulated by PPARgamma in permanent focal cerebral ischemia of rat. Neurochem Res. 2012;37(10):2099–107. doi:10.1007/s11064-012-0831-0.View ArticlePubMedGoogle Scholar
  69. Chei CL, Iso H, Yamagishi K, Tanigawa T, Cui R, Imano H, et al. Body fat distribution and the risk of hypertension and diabetes among Japanese men and women. Hypertens Res. 2008;31(5):851–7. doi:10.1291/hypres.31.851.View ArticlePubMedGoogle Scholar
  70. Araujo AA, Souza TO, Moura LM, Brito GA, Aragao KS, Araujo LS, et al. Effect of telmisartan on levels of IL-1, TNF-alpha, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model. J Clin Periodontol. 2013;40(12):1104–11. doi:10.1111/jcpe.12160.View ArticlePubMedPubMed CentralGoogle Scholar
  71. Maejima Y, Okada H, Haraguchi G, Onai Y, Kosuge H, Suzuki J, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest. 2011;91(6):932–44. doi:10.1038/labinvest.2011.45.View ArticlePubMedGoogle Scholar
  72. Yokota T, Osanai T, Hanada K, Kushibiki M, Abe N, Oikawa K, et al. Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. Heart Vessel. 2010;25(6):460–8. doi:10.1007/s00380-010-0013-4.View ArticleGoogle Scholar
  73. Inoue T, Morooka T, Moroe K, Ikeda H, Node K. Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR). Hormone Metab Res. 2007;39(5):372–6. doi:10.1055/s-2007-976544.View ArticleGoogle Scholar
  74. Inoue T, Taguchi I, Abe S, Toyoda S, Sakuma M, Node K. Inhibition of intestinal cholesterol absorption might explain cholesterol-lowering effect of telmisartan. J Clin Pharm Ther. 2011;36(1):103–10. doi:10.1111/j.1365-2710.2010.01161.x.View ArticlePubMedGoogle Scholar
  75. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123(5):1047–54. doi:10.1016/j.jaci.2009.02.026.View ArticlePubMedPubMed CentralGoogle Scholar
  76. Hasan A, Al-Ghimlas F, Warsame S, Al-Hubail A, Ahmad R, Bennakhi A, et al. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol. 2014;15:19. doi:10.1186/1471-2172-15-19.View ArticlePubMedPubMed CentralGoogle Scholar
  77. Karlsson C, Ahrné S, Molin G, Berggren A, Palmquist I, Fredrikson GN, et al. Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis. 2010;208(1):228–33. doi:10.1016/j.atherosclerosis.2009.06.019.View ArticlePubMedGoogle Scholar
  78. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000;66(4):1654–61.View ArticlePubMedPubMed CentralGoogle Scholar
  79. Duncan SH, Hold GL, Barcenilla A, Stewart CS, Flint HJ. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol. 2002;52(Pt 5):1615–20.PubMedGoogle Scholar
  80. Ranganna K, Mathew OP, Yatsu FM, Yousefipour Z, Hayes BE, Milton SG. Involvement of glutathione/glutathione S-transferase antioxidant system in butyrate-inhibited vascular smooth muscle cell proliferation. FEBS J. 2007;274(22):5962–78. doi:10.1111/j.1742-4658.2007.06119.x.View ArticlePubMedGoogle Scholar
  81. Mackie RI, Aminov RI, Hu W, Klieve AV, Ouwerkerk D, Sundset MA, et al. Ecology of uncultivated Oscillospira species in the rumen of cattle, sheep, and reindeer as assessed by microscopy and molecular approaches. Appl Environ Microbiol. 2003;69(11):6808–15.View ArticlePubMedPubMed CentralGoogle Scholar
  82. Niu Q, Li P, Hao S, Zhang Y, Kim SW, Li H, et al. Dynamic distribution of the gut microbiota and the relationship with apparent crude fiber digestibility and growth stages in pigs. Sci Report. 2015;5:9938. doi:10.1038/srep09938.View ArticleGoogle Scholar
  83. Tims S, Derom C, Jonkers DM, Vlietinck R, Saris WH, Kleerebezem M, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J. 2013;7(4):707–17. doi:10.1038/ismej.2012.146.View ArticlePubMedGoogle Scholar
  84. Vazquez-Gutierrez P, Lacroix C, Chassard C, Klumpp J, Stevens MJ, Jans C. Bifidobacterium pseudolongum Strain PV8-2, Isolated from a Stool Sample of an anemic Kenyan infant. Genome announcements. 2015;3(1). doi: 10.1128/genomeA.01469-14.
  85. O'Connor A, Quizon PM, Albright JE, Lin FT, Bennett BJ. Responsiveness of cardiometabolic-related microbiota to diet is influenced by host genetics. Mamm Genome. 2014;25(11–12):583–99. doi:10.1007/s00335-014-9540-0.View ArticlePubMedPubMed CentralGoogle Scholar
  86. Tarselli MA. Subtle niobium. Nat Chem. 2014;7(2):180. doi:10.1038/nchem.2164.View ArticlePubMedGoogle Scholar
  87. Boureau H, Decre D, Carlier JP, Guichet C, Bourlioux P. Identification of a Clostridium cocleatum strain involved in an anti-Clostridium difficile barrier effect and determination of its mucin-degrading enzymes. Res Microbiol. 1993;144(5):405–10.View ArticlePubMedGoogle Scholar
  88. Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity. 2012;20(4):738–47. doi:10.1038/oby.2011.111.View ArticlePubMedGoogle Scholar
  89. Everard A, Lazarevic V, Gaia N, Johansson M, Stahlman M, Backhed F, et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 2014;8(10):2116–30. doi:10.1038/ismej.2014.45.View ArticlePubMedPubMed CentralGoogle Scholar
  90. Million M, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, et al. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes. 2012;36(6):817–25. doi:10.1038/ijo.2011.153.View ArticleGoogle Scholar
  91. Drissi F, Merhej V, Angelakis E, El Kaoutari A, Carriere F, Henrissat B, et al. Comparative genomics analysis of Lactobacillus species associated with weight gain or weight protection. Nutr Diab. 2014;4:e109. doi:10.1038/nutd.2014.6.View ArticleGoogle Scholar
  92. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923–34. doi:10.1038/nri2449.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement

BMC Microbiology

ISSN: 1471-2180

Contact us